We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Intracameral Implants Promote Ocular Therapeutics

By HospiMedica International staff writers
Posted on 26 May 2015
Print article
Image: ENV515 particles fabricated with PRINT technology (Photo courtesy of Envisia Therapeutics).
Image: ENV515 particles fabricated with PRINT technology (Photo courtesy of Envisia Therapeutics).
Novel particle replication in non-wetting templates (PRINT) technology can be used to deliver therapeutic molecules for treating various eye diseases.

The Envisia ENV515 implant is a proprietary, fully biodegradable particle formulation of travoprost—a prostaglandin analog—with the potential for sustained intraocular pressure (IOP) reduction in both the anterior and posterior chamber of the eye over a period as long as six months, thus providing a method that could potentially address the poor medication compliance rates that exist among glaucoma patients. The product is currently undergoing an open-label first-time-in-human phase 2a clinical study that enrolled 20 glaucoma patients at various sites.

PRINT technology engineers precise particles of virtually any size, shape, and chemistry, including small molecule active pharmaceutical ingredients (API), biologic APIs, and polymeric drug delivery systems. Using biocompatible polymers and extended-release kinetics, the technology can be used to fabricate biodegradable particle implants for placement in the eye to optimize cellular uptake, intracellular localization, surface deposition, and many other performance parameters. ENV515 is under development by Envisia Therapeutics (Research Triangle Park, NC, USA).

“Poor patient compliance has long been a significant challenge in the treatment of glaucoma, making it a leading cause of preventable blindness in the United States today,” said Steven Mansberger, MD, MPH, lead investigator for the ENV515 trial and director of glaucoma services at the Devers Eye Institute (Portland, OR, USA). “Investigational products such as ENV515 have the potential to transform the treatment of glaucoma by removing compliance barriers and providing sustained reduction of intraocular pressure.”

“We are excited to advance ENV515 into clinical development only a year after forming the company, an accomplishment we are very proud of,” said Neal Fowler, CEO of Envisia. “The progress made with ENV515 underscores the power and flexibility of the PRINT technology to rapidly develop and advance promising product candidates, simultaneously, across multiple areas of interest in ophthalmology.”

Glaucoma is not curable and once there is vision loss, it cannot be regained. With an early diagnosis and effective medication it is possible to stop further loss of vision, but patient adherence to the medication is a constant challenge, and is recognized as an essential component to treatment. Several factors, including difficulty of self-administering or remembering to administer eye-drops, inconvenient or frequent dosing, and unpleasant side effects have been identified as contributing to poor glaucoma patient pharmacotherapy.

Related Links:

Envisia Therapeutics


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Medical Gas Blender
BlenderBuddy 1

Print article

Channels

Critical Care

view channel
Image: Researchers have developed an advanced shear-thinning hydrogel for aneurysm repair (Photo courtesy of TIBI)

New Hydrogel Features Enhanced Capabilities for Treating Aneurysms and Halting Progression

Aneurysms can develop in blood vessels in different body areas, often as a result of atherosclerosis, infections, inflammatory diseases, and other risk factors. These conditions lead to chronic inflammation,... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The new eye-safe laser technology can diagnose traumatic brain injury (Photo courtesy of 123RF)

Novel Diagnostic Hand-Held Device Detects Known Biomarkers for Traumatic Brain Injury

The growing need for prompt and efficient diagnosis of traumatic brain injury (TBI), a major cause of mortality globally, has spurred the development of innovative diagnostic technologies.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.